{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:33:41Z","timestamp":1783474421806,"version":"3.55.0"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Mast cell activation disease is a genetic disease entity characterized by a very pronounced clinical symptomatology with potential manifestations in virtually every organ and tissue. These arise from the inappropriate release of mast cell mediators and the accumulation of both morphologically normal and mutated mast cells. Owing to the high prevalence of the disease\u2014estimated to be up to 17%\u2014cardiologists and angiologists are frequently confronted with mast cell activation disease in their daily clinical practice, often without recognizing it. Therefore, every cardiologist and angiologist should possess basic knowledge about this disease and be aware of its cardiovascular challenges. This review summarizes the current state of knowledge on this highly complex disease, with a particular focus on the cardiovascular aspects.<\/jats:p>","DOI":"10.3389\/fcvm.2025.1705201","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T12:44:51Z","timestamp":1762778691000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular manifestations in mast cell activation disease: key insights for cardiologists and angiologists"],"prefix":"10.3389","volume":"12","author":[{"given":"Wolfgang","family":"Taumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard J.","family":"Molderings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00251-014-0768-3","article-title":"Evidence for contribution of epigenetic mechanisms in the pathogenesis of systemic mast cell activation disease","volume":"66","author":"Haenisch","year":"2014","journal-title":"Immunogenetics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e76241","DOI":"10.1371\/journal.pone.0076241","article-title":"Familial occurrence of systemic mast cell activation disease","volume":"8","author":"Molderings","year":"2013","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jaip.2023.11.041","article-title":"Low prevalence of idiopathic mast cell activation syndrome among 703 patients with suspected mast cell disorders","volume":"12","author":"Zaghmout","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/s0016-5107(99)70237-3","article-title":"Severe shock under upper gastrointestinal endoscopy in a patient with systemic mastocytosis","volume":"50","author":"Schwab","year":"1999","journal-title":"Gastrointest Endoscop"},{"key":"B5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1515\/dx-2020-0005","article-title":"Diagnosis of mast cell activation syndrome: a global \u201cconsensus-2\u201d","volume":"8","author":"Afrin","year":"2020","journal-title":"Diagnosis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","article-title":"Global classification of mast cell activation disorders: an ICD-10-CM-adjusted proposal of the ECNM-AIM consortium","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B7","doi-asserted-by":"publisher","first-page":"110862","DOI":"10.1016\/j.mehy.2022.110862","article-title":"Systemic mast cell activation disease variants and certain genetically determined comorbidities may be consequences of a common underlying epigenetic disease","volume":"163","author":"Molderings","year":"2022","journal-title":"Med Hypotheses"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s00210-023-02545-y","article-title":"A survey of the currently known mast cell mediators with potential relevance for therapy of mast cell-induced symptoms","volume":"396","author":"Molderings","year":"2023","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.amjms.2016.12.013","article-title":"Characterization of mast cell activation syndrome","volume":"353","author":"Afrin","year":"2017","journal-title":"Am J Med Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3109\/07853890.2016.1161231","article-title":"Often seen, rarely recognized: mast cell activation disease\u2014a guide to diagnosis and therapeutic options","volume":"48","author":"Afrin","year":"2016","journal-title":"Ann Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1055\/s-2006-951337","article-title":"Systemic mast cell disease with gastrointestinal symptoms\u2014a diagnostic questionnaire","volume":"131","author":"Molderings","year":"2006","journal-title":"Dtsch Med Wochenschr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s10620-020-06264-9","article-title":"Mast cell activation syndrome: a primer for the gastroenterologist","volume":"66","author":"Weinstock","year":"2021","journal-title":"Dig Dis Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","article-title":"Case-control cohort study of patients\u2019 perceptions of disability in mastocytosis","volume":"3","author":"Hermine","year":"2008","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1055\/s-0034-1370055","article-title":"Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options","volume":"139","author":"Molderings","year":"2014","journal-title":"Dtsch Med Wochenschr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1055\/a-1833-9226","article-title":"Evaluation of a tryptase depletion index for better pathologic identification of mast cell activation syndrome","volume":"61","author":"Zienkiewicz","year":"2023","journal-title":"Z Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00210-016-1247-1","article-title":"Pharmacological treatment options for mast cell activation disease","volume":"389","author":"Molderings","year":"2016","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/gut.39.1.130","article-title":"Double blind, placebo controlled food reactions do not correlate to IgE allergy in the diagnosis of staple food related gastrointestinal symptoms","volume":"39","author":"Bengtsen","year":"1996","journal-title":"Gut"},{"key":"B18","first-page":"98","article-title":"Die systemische Mastzellaktivierungserkrankung","volume":"47","author":"Molderings","year":"2024","journal-title":"Med Monatsschrift Pharm"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1056\/NEJM198510313131807","article-title":"Increased adventitial mast cells in a patient with coronary spasm","volume":"313","author":"Forman","year":"1985","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/nejm198610093151515","article-title":"Mast-cell degranulation in human hearts","volume":"315","author":"Dvorak","year":"1986","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0162-3109(95)00037-3","article-title":"Immunological characterization and functional importance of human heart mast cells","volume":"31","author":"Marone","year":"1995","journal-title":"Immunopharmacology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1600-065X.2007.00514.x","article-title":"Renin: at the heart of the mast cell","volume":"217","author":"Reid","year":"2007","journal-title":"Immunol Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.4049\/jimmunol.154.6.2855","article-title":"Human heart mast cells. Isolation, purification, ultrastructure, and immunologic characterization","volume":"154","author":"Patella","year":"1995","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0172691","DOI":"10.1371\/journal.pone.0172691","article-title":"Analysis of immune cell populations in atrial myocardium of patients with atrial fibrillation or sinus rhythm","volume":"12","author":"Smorodinova","year":"2017","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1161\/CIRCRESAHA.109.204875","article-title":"The neuropeptide substance P mediates adventitial mast cell activation and induces intraplaque hemorrhage in advanced atherosclerosis","volume":"106","author":"Bot","year":"2010","journal-title":"Circ Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.3390\/ijms20184479","article-title":"Mast cells as potential accelerators of human atherosclerosis-from early to late lesions","volume":"20","author":"Kovanen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1124\/jpet.110.172262","article-title":"Interaction between sensory C-fibers and cardiac mast cells in ischemia\/reperfusion: activation of a local renin-angiotensin system culminating in severe arrhythmic dysfunction","volume":"335","author":"Morrey","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1478-3231.2008.01839.x","article-title":"New aspects of liver abnormalities as part of the systemic mast cell activation syndrome","volume":"29","author":"Alfter","year":"2009","journal-title":"Liver Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The mastocytosis society survey on mast cell disorders: patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B31","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.hlc.2016.12.009","article-title":"Systemic mastocytosis, Kounis syndrome and coronary intervention: case report and systematic review","volume":"26","author":"Paratz","year":"2017","journal-title":"Heart Lung Circ"},{"key":"B32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary \u03b1 tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00018-013-1349-6","article-title":"The pathogenesis of cardiac fibrosis","volume":"71","author":"Kong","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3390\/ijms19010231","article-title":"Mast cells: key contributors to cardiac fibrosis","volume":"19","author":"Levick","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1111\/1523-1747.ep12468899","article-title":"Systemic mastocytosis: retrospective review of a decade\u2019s clinical experience at the Brigham and women\u2019s hospital","volume":"96","author":"Horan","year":"1991","journal-title":"J Invest Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/014107680009300309","article-title":"Unexplained loss of consciousness: systemic mastocytosis","volume":"93","author":"Valabhji","year":"2000","journal-title":"J R Soc Med"},{"key":"B37","first-page":"1","article-title":"Systemic mastocytosis: management of an unusual case with histamine (H1 and H2) antagonists and cyclooxygenase inhibition","volume":"10","author":"Crawhall","year":"1987","journal-title":"Clin Invest Med"},{"key":"B38","first-page":"311","article-title":"Clinical variability in two cases of systemic mastocytosis","volume":"105","author":"Bazan-Socha","year":"2001","journal-title":"Pol Arch Med Wewn"},{"key":"B39","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1398-9995.2005.00592.x","article-title":"Systemic mastocytosis associated with recurrent paroxysmal atrial fibrillation","volume":"60","author":"Ricciardi","year":"2005","journal-title":"Allergy"},{"key":"B40","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.annemergmed.2005.02.002","article-title":"Shortness of breath, syncope, and cardiac arrest caused by systemic mastocytosis","volume":"45","author":"Rohr","year":"2005","journal-title":"Ann Emerg Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1756-8722-4-10","article-title":"Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options","volume":"4","author":"Molderings","year":"2011","journal-title":"J Hematol Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s11739-013-1012-0","article-title":"Mastocytosis presenting as cardiac emergency","volume":"8","author":"Ridolo","year":"2013","journal-title":"Intern Emerg Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/0005-2744(78)90089-x","article-title":"Isorenin, pseudorenin, cathepsin D and renin. A comparative enzymatic study of angiotensin-forming enzymes","volume":"522","author":"Hackenthal","year":"1978","journal-title":"Biochim Biophys Acta, Enzymol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.pharmthera.2006.05.008","article-title":"Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models","volume":"112","author":"Moyazaki","year":"2006","journal-title":"Pharmacol Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/BF00173392","article-title":"Facilitatory presynaptic angiotensin receptors on the sympathetic nerves of the human saphenous vein and pulmonary artery. Potential involvement in \u00df-adrenoceptor-mediated facilitation of noradrenaline release","volume":"338","author":"Molderings","year":"1988","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.hrthm.2008.02.025","article-title":"The renin\u2013angiotensin\u2013aldosterone system (RAAS) and cardiac arrhythmias","volume":"5","author":"Iravanian","year":"2008","journal-title":"Heart Rhythm"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00210-021-02098-y","article-title":"Human histamine H2 receptors can initiate cardiac arrhythmias in a transgenic mouse","volume":"394","author":"Gergs","year":"2021","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/00005344-198307000-00004","article-title":"Cardiovascular effects of histamine infusion in man","volume":"5","author":"Vigorito","year":"1983","journal-title":"J Cardiovasc Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/01.res.58.1.1","article-title":"Histamine and cardiac arrhythmias","volume":"58","author":"Wolff","year":"1986","journal-title":"Circ Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/0090-6980(84)90033-9","article-title":"Effects of intravenous infusions of prostaglandin D2 in man","volume":"28","author":"Heavey","year":"1984","journal-title":"Prostaglandins"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1202696","DOI":"10.3389\/fcvm.2023.1202696","article-title":"Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation","volume":"10","author":"Salvucci","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1085\/jgp.20028593","article-title":"Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine","volume":"120","author":"Bucchi","year":"2002","journal-title":"J Gen Physiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1365-2125.2005.02544.x","article-title":"Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise","volume":"61","author":"Joannides","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00210-010-0565-y","article-title":"Ivabradine in patients with inappropriate sinus tachycardia","volume":"382","author":"Zellerhoff","year":"2010","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1385\/CRIAI:31:2:131","article-title":"Regulation of mast cells by \u03b2-agonists","volume":"31","author":"Peachell","year":"2006","journal-title":"Clin Rev Allergy Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/j.1440-1681.2006.04435.x","article-title":"\u03b2-adrenoceptor-mediated inhibition of mediator release from human peripheral blood-derived mast cells","volume":"33","author":"Wang","year":"2006","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaci.2014.09.004","article-title":"Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming","volume":"135","author":"Nassiri","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000356487","article-title":"Presentation of untreated systemic mastocytosis as recurrent, pulseless-electrical-activity cardiac arrests resistant to cardiac pacemaker","volume":"163","author":"Butterfield","year":"2014","journal-title":"Int Arch Allergy Immunol"},{"key":"B59","first-page":"215","article-title":"Systemic mastocytosis with myo-pericardial localization and atrioventricular block","volume":"74","author":"Thomas","year":"1981","journal-title":"Arch Mal Coeur Vaiss"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.transproceed.2007.06.047","article-title":"Correlation between mast cell density and myocardial fibrosis in congestive heart failure patients","volume":"39","author":"Batlle","year":"2007","journal-title":"Transplant Proc"},{"key":"B61","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jacc.2006.12.018","article-title":"Cardiac mast cells: implications for heart failure","volume":"49","author":"Kolck","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/ejechocard\/jep007","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography","volume":"10","author":"Nagueh","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"B64","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B65","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-198811000-00001","article-title":"Systemic mast cell disease. Analysis of 58 cases and literature review","volume":"67","author":"Travis","year":"1988","journal-title":"Medicine (Baltimore)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.prostaglandins.2009.01.001","article-title":"Survey of aspirin administration in systemic mastocytosis","volume":"88","author":"Butterfield","year":"2009","journal-title":"Prostaglandins Other Lipid Mediators"},{"key":"B67","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2222.2008.03104.x","article-title":"Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis","volume":"39","author":"Ono","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"B68","first-page":"437","article-title":"Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen","volume":"62","author":"De Vecchis","year":"2014","journal-title":"Minerva Cardioangiol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.anai.2010.04.011","article-title":"Omalizumab monotherapy for bee sting and unprovoked \u201canaphylaxis\u201d in a patient with systemic mastocytosis and undetectable specific IgE","volume":"104","author":"Kontou-Fili","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.anai.2012.02.021","article-title":"Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab","volume":"108","author":"Bell","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2340\/00015555-1687","article-title":"Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis","volume":"94","author":"Kibsgaard","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.anai.2014.05.001","article-title":"Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome","volume":"113","author":"Jagdis","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1111\/1523-1747.ep12468945","article-title":"Biochemical diagnosis of systemic mast cell disorders","volume":"96","author":"Roberts","year":"1991","journal-title":"J Invest Dermatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1582-4934.2007.00052.x","article-title":"Mast cells in vulnerable atherosclerotic plaques\u2014a view to a kill","volume":"11","author":"Lindstedt","year":"2007","journal-title":"J Cell Mol Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12016-024-08981-9","article-title":"Cellular and molecular mechanisms of mast cells in atherosclerotic plaque progression and destabilization","volume":"66","author":"Elieh-Ali-Komi","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1038\/s41598-019-38679-4","article-title":"Stress-induced mast cell activation contributes to atherosclerotic plaque destabilization","volume":"9","author":"Lagraauw","year":"2019","journal-title":"Sci Rep"},{"key":"B78","doi-asserted-by":"publisher","first-page":"112974","DOI":"10.1016\/j.intimp.2024.112974","article-title":"Pharmacological therapy targeting the immune response in atherosclerosis","volume":"141","author":"Wu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.atherosclerosis.2017.11.030","article-title":"Systemic mastocytosis associates with cardiovascular events despite lower plasma lipid levels","volume":"268","author":"Indhirajanti","year":"2018","journal-title":"Atherosclerosis"},{"key":"B80","doi-asserted-by":"crossref","first-page":"AB188","DOI":"10.1016\/j.jaci.2010.12.748","article-title":"Systemic mastocytosis presenting as Prinzmetal (variant) angina","volume":"127","author":"Ward","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11739-012-0754-4","article-title":"Kounis syndrome (allergic acute coronary syndrome): different views in allergologic and cardiologic literature","volume":"7","author":"Fassio","year":"2012","journal-title":"Intern Emerg Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijcard.2012.06.041","article-title":"Mast cell-related disorders presenting with Kounis syndrome","volume":"161","author":"Gonz\u00e1lez-de-Olano","year":"2012","journal-title":"Int J Cardiol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4274\/balkanmedj.galenos.2019.2019.5.62","article-title":"Kounis syndrome\u2014not a single-organ arterial disorder but a multisystem and multidisciplinary disease","volume":"36","author":"Kounis","year":"2019","journal-title":"Balkan Med J"},{"key":"B84","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1055\/a-2468-5553","article-title":"Gastrointestinal manifestations of systemic mast cell activation disease\u2014a practice-oriented guide to clinical picture, diagnostics and therapy","volume":"63","author":"Raithel","year":"2025","journal-title":"Z Gastroenterol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"8960","DOI":"10.3390\/ijms22168960","article-title":"Effects of primary mast cell disease on hemostasis and erythropoiesis","volume":"22","author":"Seidel","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B86","doi-asserted-by":"publisher","first-page":"658","DOI":"10.12968\/hmed.2019.80.11.658","article-title":"Raynaud\u2019s phenomenon","volume":"80","author":"Devgire","year":"2019","journal-title":"Br J Hosp Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s00104-019-0935-z","article-title":"Surgical interventions in patients with systemic mast cell activation disease: recommendations for perioperative management","volume":"90","author":"Sido","year":"2019","journal-title":"Chirurg"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00120-022-01841-4","article-title":"Cystic diseases in urology: recommendations for patients with systemic mast cell disease","volume":"61","author":"Kn\u00fcpfer","year":"2022","journal-title":"Urologie"},{"key":"B89","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.trsl.2015.12.012","article-title":"Cardiovascular symptoms in patients with systemic mast cell activation disease","volume":"174","author":"Kolck","year":"2016","journal-title":"Transl Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejphar.2015.04.050","article-title":"The impact of mast cells on cardiovascular diseases","volume":"778","author":"Kritikou","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pharmthera.2013.01.001","article-title":"Mast cells and vascular diseases","volume":"138","author":"Kennedy","year":"2013","journal-title":"Pharmacol Ther"},{"key":"B92","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00011-014-0763-z","article-title":"The role of mast cells in ischemia and reperfusion injury","volume":"63","author":"Yang","year":"2014","journal-title":"Inflammation Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41392-020-00455-6","article-title":"A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair","volume":"6","author":"Sun","year":"2021","journal-title":"Signal Transduction Targeted Ther"},{"key":"B94","doi-asserted-by":"publisher","first-page":"13607","DOI":"10.1073\/pnas.0403208101","article-title":"Mast cells: a unique source of renin","volume":"101","author":"Silver","year":"2004","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1705201\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T12:44:54Z","timestamp":1762778694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1705201\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":94,"alternative-id":["10.3389\/fcvm.2025.1705201"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1705201","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"1705201"}}